Biomarker analysis from a pathologist's view: Founding the rationale for personalised treatment of lung cancer;Biomarkeranalytik aus Sicht des Pathologen: Grundlage für eine rationale, personalisierte Tumortherapie am Beispiel von Lungenkrebs

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 56, Issue 11, 2013, Pages 1502-1508

  Buettner, R ^a   Heydt, C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Biomarker; Personalised cancer therapy; Proof of concept (PoC) studies; Therapeutic target; Tyrosinkinase inhibitors

Indexed keywords

TUMOR MARKER;

ARTICLE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG TUMOR; METHODOLOGY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PHARMACOGENETICS;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PATHOLOGY, MOLECULAR; PHARMACOGENETICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887433774     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-013-1823-1     Document Type: Article

References (50)

1. Deutsche Krebsgesellschaft E.V. (2012) Krebshäufigkeit-die aktuellen Zahlen. http://www.krebsgesellschaft.de/krebshaeufigkeit,111267.html (Zugegriffen: 02.02.2013)
2. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
3. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
5. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
6. Buettner R, Wolf J, Thomas RK (2013) Lessons to learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol (im Druck)
7. Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870
8. Ilo, Unep, Who (2001) Biomarkers in risk assessment: validity and validation: environmental health criteria no. 222. World Health Organization, Geneva
9. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
10. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
11. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from .,never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311
12. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774
13. Kohno T, Ichikawa H, Totoki Y et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-377
14. Lipson D, Capelletti M, Yelensky R et al (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384
15. Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381
16. Dutt A, Ramos AH, Hammerman PS et al (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351
17. Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78-89
18. Benson JD, Chen YN, Cornell-Kennon SA et al (2006) Validating cancer drug targets. Nature 441:451-456
19. Sellers WR (2011) A blueprint for advancing genetics-based cancer therapy. Cell 147:26-31
20. Kluter S, Simard JR, Rode HB et al (2010) Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance. Chembiochem 11:2557-2566
21. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792
22. Michalczyk A, Kluter S, Rode HB et al (2008) Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 16:3482-3488
23. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
24. Kwak EL, Sordella R, Bell DW et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670
25. Zhou W, Ercan D, Chen L et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074
26. Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711
27. Regales L, Gong Y, Shen R et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010
28. Sos ML, Rode HB, Heynck S et al (2010) Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 70:868-874
29. Xu L, Kikuchi E, Xu C et al (2012) Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET. Cancer Res 72(13):3302-3311
30. Janne PA, Boss DS, Camidge DR et al (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139
31. Miller VA, Hirsh V, Cadranel J et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:528-538
32. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937
33. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
34. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
35. Ohashi K, Sequist LV, Arcila ME et al (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America
36. Zakowski MF, Ladanyi M, Kris MG, Group MS-KCCLCO (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213-215
37. Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070-2075
38. Chmielecki J, Foo J, Oxnard GR et al (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59
39. Yap TA, Vidal L, Adam J et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972
40. Heuckmann JM, Rauh D, Thomas RK (2012) Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol 30:3417-3420
41. Walter AO,Tjin R, Haringsma H et al (2011) CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations. In: AACR-NCI-EORTC International Conference: molecular targets and cancer therapeutics. Mol Cancer Ther, San Francisco
42. Heuckmann JM, Holzel M, Sos ML et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17:7394-7401
43. Sasaki T, Okuda K, Zheng W et al (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70:10038-10043
44. Heukamp LC, Thor T, Schramm A et al (2012) Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 4:141ra191
45. Gan HK, You B, Pond GR et al (2012) Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst 104:590-598
46. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
47. Shaw AT, Camidge DR, Engelman JA et al (2012) Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30 (Abstract 7508)
48. Lin Y, Shih WJ (2004) Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics 60:482-490
49. Fabian MA, Biggs WH 3rd, Treiber DK et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336
50. Zander T, Scheffler M, Nogova L et al (2011) Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29:1701-1708